Geode Capital Management
SGMO

Geode Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Geode Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
4,570,862
+704,836
+18% +$280K ﹤0.01% 3323
2025
Q4 		$1.62M Buy
3,866,026
+579,550
+18% +$307K ﹤0.01% 3235
2025
Q3 		$2.21M Buy
3,286,476
+954,197
+41% +$514K ﹤0.01% 3146
2025
Q2 		$1.26M Buy
2,332,279
+48,829
+2% +$29K ﹤0.01% 3261
2025
Q1 		$1.5M Buy
2,283,450
+71,601
+3% +$75.8K ﹤0.01% 3155
2024
Q4 		$2.26M Buy
2,211,849
+73,540
+3% +$134K ﹤0.01% 3086
2024
Q3 		$1.85M Buy
2,138,309
+272,123
+15% +$199K ﹤0.01% 3153
2024
Q2 		$669K Sell
1,866,186
-1,497,605
-45% -$809K ﹤0.01% 3459
2024
Q1 		$2.25M Buy
3,363,791
+157,481
+5% +$114K ﹤0.01% 3070
2023
Q4 		$1.74M Buy
3,206,310
+208,384
+7% +$96.1K ﹤0.01% 3161
2023
Q3 		$1.8M Buy
2,997,926
+142,174
+5% +$152K ﹤0.01% 3104
2023
Q2 		$3.71M Buy
2,855,752
+266,421
+10% +$364K ﹤0.01% 2854
2023
Q1 		$4.56M Buy
2,589,331
+94,460
+4% +$270K ﹤0.01% 2674
2022
Q4 		$7.83M Buy
2,494,871
+112,436
+5% +$436K ﹤0.01% 2418
2022
Q3 		$11.7M Buy
2,382,435
+213,422
+10% +$1.1M ﹤0.01% 2119
2022
Q2 		$8.98M Buy
2,169,013
+76,642
+4% +$331K ﹤0.01% 2331
2022
Q1 		$12.2M Sell
2,092,371
-136,812
-6% -$813K ﹤0.01% 2220
2021
Q4 		$16.7M Buy
2,229,183
+33,840
+2% +$294K ﹤0.01% 2081
2021
Q3 		$19.8M Buy
2,195,343
+134,807
+7% +$1.33M ﹤0.01% 1965
2021
Q2 		$24.7M Buy
2,060,536
+80,576
+4% +$912K ﹤0.01% 1830
2021
Q1 		$24.8M Buy
1,979,960
+165,123
+9% +$2.23M ﹤0.01% 1739
2020
Q4 		$28.3M Buy
1,814,837
+56,003
+3% +$656K ﹤0.01% 1498
2020
Q3 		$16.6M Sell
1,758,834
-13,668
-0.8% -$148K ﹤0.01% 1651
2020
Q2 		$15.9M Buy
1,772,502
+83,477
+5% +$774K ﹤0.01% 1660
2020
Q1 		$10.8M Buy
1,689,025
+104,456
+7% +$775K ﹤0.01% 1696
2019
Q4 		$13.3M Buy
1,584,569
+51,601
+3% +$474K ﹤0.01% 1814
2019
Q3 		$13.9M Buy
1,532,968
+46,818
+3% +$525K ﹤0.01% 1709
2019
Q2 		$16M Buy
1,486,150
+233,677
+19% +$2.49M ﹤0.01% 1640
2019
Q1 		$11.9M Buy
1,252,473
+123,108
+11% +$1.26M ﹤0.01% 1774
2018
Q4 		$13M Buy
1,129,365
+15,750
+1% +$196K ﹤0.01% 1604
2018
Q3 		$18.9M Buy
1,113,615
+32,047
+3% +$487K 0.01% 1450
2018
Q2 		$15.4M Buy
1,081,568
+243,573
+29% +$4.05M ﹤0.01% 1550
2018
Q1 		$15.9M Sell
837,995
-2,109
-0.3% -$45.1K 0.01% 1425
2017
Q4 		$13.8M Buy
840,104
+19,087
+2% +$284K ﹤0.01% 1515
2017
Q3 		$12.3M Buy
821,017
+93,402
+13% +$1.03M ﹤0.01% 1574
2017
Q2 		$6.4M Buy
727,615
+93,651
+15% +$601K ﹤0.01% 1982
2017
Q1 		$3.3M Buy
633,964
+19,331
+3% +$77.5K ﹤0.01% 2368
2016
Q4 		$1.87M Buy
614,633
+101,995
+20% +$371K ﹤0.01% 2664
2016
Q3 		$2.37M Buy
512,638
+12,287
+2% +$62.5K ﹤0.01% 2450
2016
Q2 		$2.9M Buy
500,351
+15,493
+3% +$98.7K ﹤0.01% 2236
2016
Q1 		$2.93K Buy
484,858
+26,301
+6% +$158K ﹤0.01% 2201
2015
Q4 		$4.19M Buy
458,557
+25,887
+6% +$199K ﹤0.01% 1989
2015
Q3 		$2.44M Buy
432,670
+1,994
+0.5% +$16.4K ﹤0.01% 2310
2015
Q2 		$4.78M Buy
430,676
+19,549
+5% +$252K ﹤0.01% 1923
2015
Q1 		$6.45M Buy
411,127
+3,727
+0.9% +$57.7K ﹤0.01% 1708
2014
Q4 		$6.2M Sell
407,400
-37,945
-9% -$461K ﹤0.01% 1688
2014
Q3 		$4.8M Buy
445,345
+60,844
+16% +$795K ﹤0.01% 1793
2014
Q2 		$5.87M Buy
384,501
+18,140
+5% +$261K ﹤0.01% 1684
2014
Q1 		$6.62M Buy
366,361
+22,373
+7% +$431K ﹤0.01% 1553
2013
Q4 		$4.78M Buy
343,988
+81,641
+31% +$940K ﹤0.01% 1744
2013
Q3 		$2.75M Buy
262,347
+42,271
+19% +$420K ﹤0.01% 1980
2013
Q2 		$1.72M Buy
+220,076
New +$1.92M ﹤0.01% 2136

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management's SGMO Position: Q1 2026 in Review

Geode Capital Management increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 18% in Q1 2026, buying an estimated $280K and bringing the position to 4,570,862 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3323.

Geode Capital Management first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $28.3M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Geode Capital Management held 4,570,862 shares of SANGAMO THERAPEUTICS INC worth $1.13M as of Q1 2026.
  • Geode Capital Management bought 704,836 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $280K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3323 holding.
  • Geode Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Geode Capital Management's SANGAMO THERAPEUTICS INC position peaked at $28.3M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.